RxDoctor Payments Data

Grace Efunbajo

Family · Riverdale, MDNPI 1942827258

Payments from drug & device makers

$2,518in general payments, 2019–2025

Across 120 payments — averaging $20.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$572
  • AstraZeneca$400
  • Lilly USA, LLC$162
  • Vanda Pharmaceuticals Inc.$133
  • Bayer$106
  • Astellas Pharma US Inc$99
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$2,518100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,518 in reported general payments places this provider in the 85th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$24,136
Medicare patients
151
Services billed
280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide25$24,184
OzempicSemaglutide15$22,932
MounjaroTirzepatide13$22,783
EliquisApixaban28$19,705
FarxigaDapagliflozin Propanediol15$8,536
Incruse ElliptaUmeclidinium Bromide18$6,911
Amlodipine Besylate135$1,158
Atorvastatin Calcium107$1,027
Metoprolol Succinate51$901
Albuterol Sulfate HfaAlbuterol Sulfate43$846
Nano 2nd Gen Pen NeedlePen Needle, Diabetic14$813
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$766
Metformin Hcl ErMetformin Hcl66$675
Fluticasone Propionate34$542
Losartan Potassium51$456

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$162$46,96638 claims
Novo NordiskOzempic$572$22,93215 claims
PfizerEliquis$85$19,70528 claims
AstraZenecaFarxiga$400$8,53615 claims
GSKIncruse Ellipta$82$6,91118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,843 family providers in Maryland.

Other family in Riverdale

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →